

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/I120B48A3CEEN.html>

Date: February 2018

Pages: 49

Price: US\$ 3,500.00 (Single User License)

ID: I120B48A3CEEN

Abstracts

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Pipeline Review, H1 2018

SUMMARY

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) pipeline Target constitutes close to 8 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes. The latest report Insulin Like Growth Factor II - Pipeline Review, H1 2018, outlays comprehensive information on the Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Insulin-like growth factor 2 (IGF-2) is a protein hormone. IGF-2 is influenced by placental lactogen and plays a role in fetal development. It undergoes glucose-mediated co-secretion with insulin and acts as physiological amplifier of glucose-mediated insulin secretion. It exhibits osteogenic properties by increasing osteoblast mitogenic activity through phosphoactivation of MAPK1 and MAPK3.

The molecules developed by companies in Phase II and Preclinical stages are 2 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 3 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Central Nervous System which include indications Acute

Ischemic Stroke, Amyotrophic Lateral Sclerosis, Breast Cancer, Metastatic Breast Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Neuroblastoma, Non-Small Cell Lung Cancer, Parkinson's Disease and Solid Tumor.

Furthermore, this report also reviews key players involved in Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)

The report reviews Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics and enlists all their major and minor projects

The report assesses Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics based on mechanism of

action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Overview

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Companies Involved in Therapeutics Development

Boehringer Ingelheim GmbH

Genervon Biopharmaceuticals LLC

Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Drug Profiles

GM-6 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-610.27 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-630 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-7085 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress**Recombinant Protein to Inhibit IGF-1 and IGF-2 for Breast Cancer - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****Recombinant Proteins to Inhibit IGF-2 for Oncology - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****Small Molecules to Inhibit IGF-2 for Oncology - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****xentuzumab - Drug Profile****Product Description****Mechanism Of Action****R&D Progress****Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Dormant Products****Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Discontinued Products****Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) - Product Development Milestones****Featured News & Press Releases****Dec 08, 2017: GM604 Is a Multi-Target Regulator That Provides a Novel Treatment Strategy for ALS****Mar 23, 2017: Confidential Data from Genervon ALS Phase 2A Clinical Trial Were Released and Published****Jan 10, 2017: Genervon Releases ALS, PD and AD Disease Associated Gene Lists Modulated by GM6 and Encourages Researchers to Explore New Discoveries beyond Single Target Drug Development Paradigm****Dec 27, 2016: ALS and Alzheimer's disease bioinformatics reports confirm GM6's role as regulator of disease-relevant pathways****Jun 06, 2016: GENERVON GM604 received EUs orphan drug designation to treat ALS****May 23, 2016: ALS Patients from Around the World Responding Well to Genervons GM604****May 03, 2016: GM604 to Be Granted "Orphan Drug" Status in Europe****Sep 22, 2015: Genervon GM604 Reduced TDP-43 Protein Aggregates and Slowed Down ALS Progression**

Jun 29, 2015: Genervon Filed Patent for Using GM604 Modulations of ALS Disease Biomarkers Showing Homeostasis, Leading to Prognosis and Therapeutic Treatment for ALS Disease

Apr 17, 2015: Amyotrophic Lateral Sclerosis Statement; FDA

Jan 08, 2015: Genervon Announces ALS Compassionate Use Results

Oct 19, 2014: Genervon Announces ALS and PD Phase 2a Trial Results

Jun 30, 2014: Genervon Announces Biomarker Data from GAL5-001 Clinical Trial for ALS

Apr 28, 2014: Genervon Successfully Completes its Phase 2a Clinical Trial for ALS

Mar 03, 2014: FDA Grants "Orphan Drug" Designation for Genervon's Breakthrough Multi-Target ALS Bio-Drug GM604

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Boehringer Ingelheim GmbH, H1 2018
Pipeline by Genervon Biopharmaceuticals LLC, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

Boehringer Ingelheim GmbH

Genervon Biopharmaceuticals LLC

I would like to order

Product name: Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2)
- Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/l120B48A3CEEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/l120B48A3CEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

